Insider Selling: Gilead Sciences (NASDAQ:GILD) CFO Sells $435,870.00 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CFO Andrew Dickinson sold 3,000 shares of the business’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $145.29, for a total value of $435,870.00. Following the completion of the sale, the chief financial officer owned 164,096 shares in the company, valued at approximately $23,841,507.84. The trade was a 1.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gilead Sciences Stock Down 0.5%

Shares of NASDAQ GILD opened at $150.11 on Friday. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The stock has a market capitalization of $186.13 billion, a PE ratio of -56.22 and a beta of 0.33. Gilead Sciences, Inc. has a one year low of $108.46 and a one year high of $157.29. The business’s fifty day moving average price is $139.98 and its 200-day moving average price is $136.32.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping the consensus estimate of ($7.25) by $0.50. The company had revenue of $7.80 billion during the quarter, compared to analyst estimates of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The firm’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter last year, the firm posted $2.01 EPS. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post -0.48 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be given a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.2%. Gilead Sciences’s payout ratio is -122.85%.

Institutional Trading of Gilead Sciences

Several institutional investors and hedge funds have recently bought and sold shares of the company. Essex Financial Services Inc. increased its holdings in shares of Gilead Sciences by 0.9% in the fourth quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock worth $948,000 after purchasing an additional 71 shares during the period. Davidson Trust Co. boosted its stake in Gilead Sciences by 4.1% during the first quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company’s stock valued at $262,000 after buying an additional 74 shares during the period. Financial Connections Group Inc. grew its position in Gilead Sciences by 30.2% during the first quarter. Financial Connections Group Inc. now owns 328 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 76 shares in the last quarter. Wilkerson Advisory Group LLC grew its position in Gilead Sciences by 54.2% during the first quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 78 shares in the last quarter. Finally, Balboa Wealth Partners increased its stake in Gilead Sciences by 2.7% in the 1st quarter. Balboa Wealth Partners now owns 3,057 shares of the biopharmaceutical company’s stock worth $426,000 after acquiring an additional 79 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms recently commented on GILD. Zacks Research raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Monday, August 31st. Barclays lowered their target price on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 29th. Truist Financial cut their price target on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a report on Tuesday, July 7th. HSBC lifted their price target on Gilead Sciences from $155.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $170.00 price objective on shares of Gilead Sciences in a research note on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $158.78.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company’s research focuses primarily on virology, oncology, inflammation and related areas, with products serving patients in the United States and international markets.

Gilead is best known for its HIV treatments, including Biktarvy, Genvoya, Descovy and other antiretroviral therapies. Its portfolio also includes medicines for viral hepatitis, such as Epclusa and Vemlidy, and Veklury (remdesivir), an antiviral treatment for COVID-19.